- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Trident Royalties PLC
Impact Minerals Limited
Purpose Bitcoin ETF
Ramp Metals
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Theralase Technologies announced it received a second US patent for their lead anti-cancer compound technology.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced it received a second US patent for their lead anti-cancer compound technology.
As quoted in the press release:
The patent deals with the composition of tunable metal-based thiophene PDCs used as therapeutic agents and as in-vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology, including: cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases and for pathogen disinfection.
Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase continues to build its patent portfolio for its anti-cancer division, providing protection from competition as the Company advances towards commercialization of this technology through the clinical study process. The Company is actively involved in the second phase of a Phase Ib clinical trial for Non-Muscle Invasive Bladder Cancer (“NMIBC“) focused on enrolling and treating the next six patients at the therapeutic dose of its lead PDC, TLD-1433 (0.70 mg/cm2).”
Click here to read the full press release.
Source: www.accesswire.com
Outlook Reports
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2332.04 | -54.80 | |
Silver | 27.21 | -1.36 | |
Copper | 4.51 | -0.01 | |
Oil | 83.28 | +0.14 | |
Heating Oil | 2.56 | +0.01 | |
Natural Gas | 1.78 | +0.03 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.